Loading...
Genus plc
GENSF•PNK
Healthcare
Biotechnology
$33.29
$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $350.20M in Q2 2022 to $335.20M in Q4 2023. Gross profit remained healthy with margins at 100% in Q4 2023 compared to 73% in Q2 2022. Operating income hit -$14.90M last quarter, sustaining a consistent -4% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $11.30M. Net income dropped to -$5.60M, while earnings per share reached -$0.09. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan